InsidersTradesSigma
Total declarations
Companies
▲ Purchases (18 ops.)
▼ Sales (5 ops.)
Insider track record
OtherDisclosed buys
18
Disclosed sells
5
T+90 hit rate
10%
T+90 mean return
-34.7%
Across 10 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by ARMISTICE CAPITAL, LLC. Director active across 7 companies, notably Aytu Biopharma, INC. Cumulatively, 32 disclosures have been logged. Split: 18 buys · 5 sells. Total volume traded: €8.4m. Activity tracked since 20 March 2021. The latest transaction was filed on 26 June 2023 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Declarations32 total
2,746,138 shares@ US$0.612554.8% of flowCommon StockSEC:0000899243-23-016659:0
334 shares@ US$3.950.0% of flowCommon StockSEC:0000899243-23-004412:0
26,000 shares@ US$0.7010.0049% mcap1.3% of flowCommon StockSEC:0000899243-22-010904:0
Ideal exit: 5 Dec 2022 (T+270)
50,000 shares@ US$0.71390.0096% mcap2.5% of flowCommon StockSEC:0000899243-22-009744:0
Ideal exit: 28 Nov 2022 (T+270)
100,000 shares@ US$0.80090.021% mcap5.6% of flowCommon StockSEC:0000899243-22-008145:0
Ideal exit: 21 Nov 2022 (T+270)
150,000 shares@ US$0.8150.032% mcap8.5% of flowCommon StockSEC:0000899243-22-007249:0
Ideal exit: 14 Nov 2022 (T+270)
206,300 shares@ US$0.883330.6% of flowCommon StockSEC:0000899243-22-002693
Ideal exit: 15 Oct 2022 (T+270)
206,300 shares@ US$0.88330.048% mcap12.6% of flowCommon StockSEC:0000899243-22-002693:0
Ideal exit: 15 Oct 2022 (T+270)
57,300 shares@ US$1.043310.1% of flowCommon StockSEC:0000899243-22-002025
Ideal exit: 9 Oct 2022 (T+270)
57,300 shares@ US$1.04330.016% mcap4.1% of flowCommon StockSEC:0000899243-22-002025:0
Ideal exit: 9 Oct 2022 (T+270)
137,900 shares@ US$1.036824.3% of flowCommon StockSEC:0000899243-22-001618
Ideal exit: 4 Oct 2022 (T+270)
137,900 shares@ US$1.03680.038% mcap10.0% of flowCommon StockSEC:0000899243-22-001618:0
Ideal exit: 4 Oct 2022 (T+270)
95,455 shares@ US$2.26230.054% mcap14.4% of flowCommon StockSEC:0000899243-21-036402:0
Ideal exit: 12 Jun 2022 (T+270)
95,455 shares@ US$2.26236.5% of flowCommon StockSEC:0000899243-21-036402
Ideal exit: 12 Jun 2022 (T+270)
30,000 shares@ US$2.75469.3% of flowCommon StockSEC:0000899243-21-033505:0
Ideal exit: 13 May 2022 (T+270)
30,000 shares@ US$2.754623.6% of flowCommon StockSEC:0000899243-21-033505
Ideal exit: 13 May 2022 (T+270)
100,000 shares@ US$2.685930.1% of flowCommon StockSEC:0001567619-21-014631:0
Ideal exit: 1 May 2022 (T+270)
100,000 shares@ US$2.685976.4% of flowCommon StockSEC:0001567619-21-014631
Ideal exit: 1 May 2022 (T+270)
68,188 shares@ US$2.6922.1% of flowCommon StockSEC:0001567619-21-014361:0
68,188 shares@ US$2.6922.1% of flowCommon StockSEC:0001567619-21-014361
852,500 shares@ US$4.8047.9% of flowCommon StockSEC:0000899243-21-030722:0
852,500 shares@ US$4.8047.9% of flowCommon StockSEC:0000899243-21-030722
1,479,713 sharesCommon StockSEC:0000919574-21-004321
1,479,713 sharesCommon StockSEC:0000919574-21-004321:0
388,045 shares@ US$6.5250.0% of flowCommon StockSEC:0000919574-21-004191
25 of 32 declarations
About ARMISTICE CAPITAL, LLC
ARMISTICE CAPITAL, LLC is a significant shareholder of AYTU BIOPHARMA, INC.
